

=> s jp2004002321/pn
L9 1 JP2004002321/PN

=> d bib abs

L9 ANSWER 1 OF 1 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 2003-779042 [73] WPIDS
DNC C2003-214487
TI Agent used for treating hormone dependent diseases comprises luteinizing hormone release hormone receptor agonist and androgen receptor agonist.
DC B05
IN HARA, T; KUSAKA, M
PA (TAKE) TAKEDA CHEM IND LTD
CYC 102

PI WO 2003075958 A1 20030918 (200373)* JA 79
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT
RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA
ZM ZW

JP 2004002321 A 20040108 (200405) 39<--

AU 2003211877 A1 20030922 (200431)

ADT WO 2003075958 A1 WO 2003-JP2783 20030310; JP 2004002321 A JP 2003-62996
20030310; AU 2003211877 A1 AU 2003-211877 20030310

FDT AU 2003211877 A1 Based on WO 2003075958

PRA1 JP 2002-65734 20020311

AN 2003-779042 [73] WPIDS

AB WO2003075958 A UPAB: 20031112

NOVELTY - Agent comprises:

(i) a luteinizing hormone release hormone (LHRH) receptor agonist,
and

(ii) an androgen receptor agonist.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(a) the use of an androgen receptor agonist or its salt in a preparation containing a LHRH receptor agonist or antagonist or its salt;
(b) the use of an androgen agonist or its salt for treating bone metastasizing prostatic cancer, and
(c) the use of a non-steroidal androgen agonist or its salt for treating or preventing prostate cancer.

ACTIVITY - Endocrine-Gen.; Cytostatic.

No biological data is given.

MECHANISM OF ACTION - LHRH receptor agonist; Androgen receptor agonist.

USE - Used for treating and preventing hormone dependent diseases such as prostate cancer (including bone metastasizing prostate cancer).

ADVANTAGE - The combination allows the add-back of androgen which is suppressed by LHRH agonists, reducing side effects.

Dwg. 0/0

=>